People · Operator
Named in public records as an officer, director or promoter · active 2012–2018 · Biotechnology, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | — | Biotechnology | Series C | $108.8M | $3.1B | 2012 |
| Collegium Pharmaceutical, Inc | — | Pharmaceuticals | Series C | $97.5M | $701.8M | 2015 |
| CARISMA Therapeutics Inc. | — | Biotechnology | Series C | $95.0M | $1.3B | 2018 |
| NovaSom, Inc | — | Other Health Care | Series B | $53.9M | $82.0M | 2014 |
Eran Nadav at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eran Nadav on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Heffernan | 2 | 5 |
| David Hirsch | 1 | 16 |
| Patrick Heron | 1 | 11 |
| Adele Oliva | 1 | 9 |
| Ben Auspitz | 1 | 9 |
| Briggs Morrison | 1 | 8 |
| John Freund | 1 | 7 |
| Stephen Hoffman | 1 | 7 |
| James A. Datin | 1 | 6 |
| Gino Santini | 1 | 5 |
| D. Keith Grossman | 1 | 5 |
| Adele C. Oliva | 1 | 5 |
| Bruce Peacock | 1 | 5 |
| Paul Brannelly | 1 | 4 |
| Steven Kelly | 1 | 4 |
| Margarita Chavez | 1 | 4 |
| Michael Poisel | 1 | 4 |
| William Aliski | 1 | 4 |
| Patrick N. Heron | 1 | 3 |
| Steven N. Tannenbaum | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.